Johnson & Johnson’s TAR-200 Receives USFDA Priority Review for High-Risk Non-Muscle Invasive Bladder Cancer Treatment

Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for its New Drug Application (NDA) of TAR-200 – an innovative intravesical gemcitabine-releasing system developed for the treatment of BCG-unresponsive high-risk non-muscle invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.

“TAR-200 is a novel advancement in localized drug delivery that we haven’t seen in decades,” said Dr. Yusri Elsayed, Global Therapeutic Area Head, Oncology, Johnson & Johnson Innovative Medicine. “This Priority Review emphasizes our commitment to change the current treatment paradigm in bladder cancer.”

🧪 Backed by Promising Clinical Data

The NDA is supported by strong results from the Phase 2b SunRISe-1 clinical trial, which showed:

82.4% Complete Response (CR) rate
Over half (52.9%) of those patients remained cancer-free for at least 1 year after achieving CR
95% Confidence Interval (CI): 72.6% to 89.8%

Most side effects were mild to moderate, with common ones (≥10%) including:

Frequent urination (pollakiuria)
Pain during urination (dysuria)
Urinary tract infection
Urgency, hematuria, noninfective cystitis, and bladder pain

Importantly, no systemic side effects were reported. The data was presented at the April 2025 AUA Annual Meeting.

💊 About TAR-200?

TAR-200 is an investigational drug delivery system that slowly releases gemcitabine directly into the bladder over three weeks. It’s placed non-surgically via a catheter by a healthcare provider in an outpatient setting — no general anesthesia or hospital admission required.

Key Features:

First-of-its-kind intravesical drug-releasing system (iDRS)
Provides sustained local delivery of chemotherapy
Suitable for patients unwilling or unfit for radical cystectomy

🚀 Regulatory Timeline & Studies

Breakthrough Therapy Designation (BTD): Granted in December 2023
NDA Submission under Real-Time Oncology Review (RTOR): Initiated in January 2025
Priority Review Granted: July 2025

TAR-200 is currently being evaluated in multiple clinical trials:

SunRISe-1, -3, -5 for NMIBC
SunRISe-4 for MIBC

🔍 A Game-Changer in Bladder Cancer Treatment

For over 40 years, there has been minimal change in the standard of care for high-risk bladder cancer. Patients who don’t respond to BCG therapy often face limited options. If approved, TAR-200 could provide a bladder-sparing, non-invasive alternative with strong efficacy and better quality of life.